The Effect of Hesperidin on Glucose / Insulin Metabolism

Obesity Clinical Trial

Official title:

The Effect of Hesperidin Administration on Glucose / Insulin Metabolism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02610491
• Other study ID #: 143036
• Status: Completed
• Phase: Phase 2
• First received: November 16, 2015
• Last updated: November 19, 2015
• Start date: February 2015
• Est. completion date: October 2015

Study information

• Verified date: November 2015
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

Metabolic Syndrome (MS) is a well-known group of obesity-related metabolic disorders including insulin resistance (IR), dyslipidemia and hypertension (HTN). In addition, overweight has a causal relationship with a chronic low grade systemic inflammatory condition and increased intestinal permeability. Over the last decade, this multiplex disorder has progressively become a major worldwide public health problem, because of its association with increased risk of type 2 diabetes mellitus (DM2), atherosclerotic cardiovascular disease and all-cause mortality. Scientific evidence for measures to improve cardiometabolic and intestinal health by non-pharmaceutical means are of urgent need. Administration of the flavonoid hesperidin to those at risk may have beneficial effects on glucose / insulin metabolism, lipid metabolism, blood pressure, heart rate, pro-inflammatory and oxidative stress biomarkers and gut barrier function.

Objective: To determine the 12-week effect of daily administration of hesperidin on the main cardiometabolic disorders related to MS as assessed by investigation of glucose/insulin metabolism, blood lipid profile, blood pressure, heart rate, body composition and gut barrier function in subjects at risk for MS.

Study design: This is a randomized, double-blind, placebo-controlled study with parallel design.

Study population: Healthy (male/female) volunteers, age 18-65, at risk for metabolic syndrome (presenting with 2 out of 5 of the components from NCEP-ATP-III criteria).

Intervention: Participants will be randomly assigned to one of the intervention groups. One group will receive one daily dose of hesperidin capsules while the other group receives identical looking placebo capsules for a period of 12 weeks. The capsules will have to be ingested with a glass of water every morning just before breakfast.

Main study parameters/endpoints: The primary efficacy parameter of this study is the oral glucose tolerance test (OGTT), a validated surrogate endpoint to study the β-cell function and insulin sensitivity. Secondary endpoints entail the evaluation of effects of daily administration of hesperidin on lipid profile (blood measurements), blood pressure and heart rate, body composition, low-grade inflammation biomarkers (blood measurements) and gut barrier function (blood measurements, fecal samples, urine collection).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: October 2015
• Est. primary completion date: October 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subjects at risk for metabolic syndrome: a combination of 2 out of 5 components:

• Waist circumference: men > 102 cm / women > 88 cm

• Triglycerides: = 1.7 mmol/l

• HDL-cholesterol: men = 1.0 mmol/l / women = 1.3 mmol/l

• Systolic blood pressure: = 130 mmHg or diastolic blood pressure: = 85 mmHg

• Fasted serum glucose = 6.1 mmol/L

Exclusion Criteria:

• Type 2 diabetes mellitus (defined as fasting plasma glucose =7.0 mmol/l)

• Gastroenterological diseases or abdominal surgery

• Cardiovascular diseases, cancer, liver or kidney malfunction, thyroid disorders, disease with a life expectancy shorter than 5 years

• Self-admitted HIV-positive status

• Abuse of products; alcohol (> 20 alcoholic consumptions per week) and drugs

• Smoking

• Plans to lose weight or following a hypocaloric diet during the study period

• Weight gain or loss > 3 kg in previous 3 months

• Use of medication interfering with endpoints

• Use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine

• Hormone replacement therapy (women).

• Use of antibiotics in the 90 days prior to the start of study

• Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator) in the 180 days prior to the study

• Known pregnancy (assessed by a pregnancy test before start of study) or lactation

• Blood donation within 3 months before study period

• Failure to comply prohibited intake of hesperidin containing food products during study period. A list with forbidden products will be provided to participants

• History of any side effects towards the intake of flavonoids or citrus fruits

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Metabolic Syndrome
• Metabolic Syndrome X
• Obesity

Intervention

Dietary Supplement:
• Hesperidin
Citrus peel extract
• Placebo
Cellulose

Locations

Country	Name	City	State
Netherlands	MUMC+	Maastricht	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect on blood glucose concentrations measured by oral glucose tolerance test		12 weeks	No
Secondary	Effect on blood lipid profile		12 weeks	No
Secondary	Effect on blood pressure		12 weeks	No
Secondary	Effect on body composition measured by BMI		12 weeks	No
Secondary	Effect on low-grade inflammation measured by blood concentration of TNFalfa		12 weeks	No
Secondary	Effect on low-grade inflammation measured by blood concentration of interleukin-6		12 weeks	No
Secondary	Effect on gut barrier function measured by a sugar test		12 weeks	No